WebDronedarone (Multaq), an analogue of amiodarone (Cordarone), was designed to cause fewer adverse effects than the parent compound. Studies have indeed shown dronedarone to be safer than amiodarone, but less effective. Dronedarone, sold under the brand name Multaq, is a medication by Sanofi-Aventis, mainly for the indication of cardiac arrhythmias. It was approved by the FDA on July 2, 2009. It was recommended as an alternative to amiodarone for the treatment of atrial fibrillation and atrial flutter in people whose hearts have either returned to normal rhythm or who undergo drug therapy or electric shoc…
Multaq (Dronedarone Tablets): Uses, Dosage, Side Effects ... - RxList
Web24 apr. 2024 · Given the risks of bleeding and stroke in the patient, the treatment approach was to increase the platelet count using ITP therapies (starting with low-dose corticosteroids) until it is above 50 × 10 9 /L, and then to administer anticoagulation. Patient 2 Web12 aug. 2024 · Multaq is also contraindicated in patients with liver failure, and with medications and/or supplements that prolong the QT interval. Finally, Multaq is only indicated for patients with intermittent afib, as use in patients with permanent atrial fibrillation has been demonstrated to increase mortality in another landmark clinical trial. meavy view retirement home
Multaq - European Drugs Reference Encyclopedia
WebMULTAQ should only be initiated in patients in sinus rhythm who are receiving appropriate antithrombotic therapy. New Onset or Worsening Heart Failure New onset or worsening … Webdiscontinuation of therapy with MULTAQ were gastrointestinal disorders (3.2% of patients versus . 1.8% in the placebo group). The most frequent adverse reactions observed with dronedarone 400 mg twice daily in the 5 studies . were diarrhoea, nausea and vomiting, fatigue and asthenia. WebA dynamic performance-driven specialist with excellent communication skills combined with twelve years proven record of accomplishment in athletic … pegylation antibody